Apellis Pharmaceuticals（纳斯达克代码：APLS）报告的季度每股亏损为$(0.29)，比分析师的共识预期$(0.37)高出21.62%。这是与去年同期每股亏损$(0.73)相比增加了60.27%。公司报告的季度销售额为2.1253亿美元，高于分析师的共识预期1.9835亿美元，高出7.15%。这是与去年同期销售额1.4638亿美元相比增加了45.19%。
以上内容来自Benzinga Earnings专栏，原文如下：
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 60.27 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $212.53 million which beat the analyst consensus estimate of $198.35 million by 7.15 percent. This is a 45.19 percent increase over sales of $146.38 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。